Abstract
Alzheimer's disease (AD) is a slowly progressing disease and the evaluation of clinical effects of candidate drugs requires large clinical cohorts as well as long treatment trials. There is a great need for central biomarkers and translatable pre-clinical models to provide early indication of treatment effects. We set out to evaluate the guinea pig as a clinically translatable model looking at Aβ peptides. Our data demonstrate homology between β-amyloid (Aβ) peptide pattern in cerebrospinal fluid (CSF) from human and guinea pig. To further evaluate the model a novel γ-secretase modulator was used. Dose and time response studies confirm the modulatory properties with a statistically significant decrease in relative levels of Aβ1-40, Aβ1-42 and increase in Aβ1-37 already one hour after administration. We suggest that the guinea pig is a compelling pre-clinical model for evaluating and translating central effects on Aβ peptides in CSF after treatment. Further quantitative data are needed to confirm our data together with data from clinical trials in order to back translate and validate our findings.
Keywords: Alzheimer's disease, β-amyloid (Aβ), biomarkers, CSF, plasma, γ-secretase modulator, pre-clinical model, translation, treatment.
Current Pharmaceutical Design
Title:Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Volume: 20 Issue: 15
Author(s): Erik Portelius, Paulina Appelkvist, Kia Stromberg and Kina Hoglund
Affiliation:
Keywords: Alzheimer's disease, β-amyloid (Aβ), biomarkers, CSF, plasma, γ-secretase modulator, pre-clinical model, translation, treatment.
Abstract: Alzheimer's disease (AD) is a slowly progressing disease and the evaluation of clinical effects of candidate drugs requires large clinical cohorts as well as long treatment trials. There is a great need for central biomarkers and translatable pre-clinical models to provide early indication of treatment effects. We set out to evaluate the guinea pig as a clinically translatable model looking at Aβ peptides. Our data demonstrate homology between β-amyloid (Aβ) peptide pattern in cerebrospinal fluid (CSF) from human and guinea pig. To further evaluate the model a novel γ-secretase modulator was used. Dose and time response studies confirm the modulatory properties with a statistically significant decrease in relative levels of Aβ1-40, Aβ1-42 and increase in Aβ1-37 already one hour after administration. We suggest that the guinea pig is a compelling pre-clinical model for evaluating and translating central effects on Aβ peptides in CSF after treatment. Further quantitative data are needed to confirm our data together with data from clinical trials in order to back translate and validate our findings.
Export Options
About this article
Cite this article as:
Portelius Erik, Appelkvist Paulina, Stromberg Kia and Hoglund Kina, Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model, Current Pharmaceutical Design 2014; 20 (15) . https://dx.doi.org/10.2174/13816128113199990499
DOI https://dx.doi.org/10.2174/13816128113199990499 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Prediction of Comparative Inhibition Efficiency for a Novel Natural Ligand, Galangin Against Human Brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Basal Ganglia Enlarged Perivascular Spaces are Linked to Cognitive Function in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Prion Protein Misfolding
Current Molecular Medicine Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets Fish Oil Prevents Oxidative Stress and Exerts Sustained Antiamnesic Effect After Global Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Status Epilepticus: An Overview
Current Drug Metabolism Markers of Systemic Inflammation in Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Joint Occurrence of Pain and Sleep Disturbances in People with Dementia. A Systematic Review
Current Alzheimer Research Cytochrome P450 in Neurological Disease
Current Drug Metabolism Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Kleptomania: Differential Diagnosis and Treatment Modalities
Current Psychiatry Reviews A New “Era” for the α7-nAChR
Current Drug Targets Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets The Role of HIV-1 DNA as an Additional Marker of HIV-1 Infection
Current HIV Research Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research